Michael Rowe
Chief Executive Officer at EYENOVIA, INC.
Net worth: 23 411 $ as of 2024-04-29
Profile
Michael M.
Rowe is currently the Chief Executive Officer & Director at Eyenovia, Inc. He previously worked as the Senior Vice President-Global Marketing at Gene Express, Inc. From 2016 to 2018, he was the Head-Global Strategic Marketing at Aerie Pharmaceuticals, Inc. Prior to that, he held the position of Head-Corporate Competitive Intelligence at Allergan Ltd.
(Ireland) from 2010 to 2016.
Mr. Rowe completed his undergraduate degree at Stony Brook University and his graduate degree at Rensselaer Polytechnic Institute.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
EYENOVIA, INC.
0.07% | 2024-04-15 | 32,927 ( 0.07% ) | 23 411 $ | 2024-04-29 |
Michael Rowe active positions
| Companies | Position | Start |
|---|---|---|
| EYENOVIA, INC. | Chief Executive Officer | 2022-07-31 |
Former positions of Michael Rowe
| Companies | Position | End |
|---|---|---|
| AERIE PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2018-05-31 |
| ALLERGAN PLC | Corporate Officer/Principal | 2016-01-31 |
Gene Express, Inc.
 Gene Express, Inc. Miscellaneous Commercial ServicesCommercial Services Gene Express, Inc. provides research and development on molecular diagnostic products. It also provides genomic data to accelerate and enable drug and molecular diagnostic development. The company was founded in 1992 and is headquartered in Wilmington, NC. | Sales & Marketing | - |
Training of Michael Rowe
| Stony Brook University | Undergraduate Degree |
| Rensselaer Polytechnic Institute | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| EYENOVIA, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Gene Express, Inc.
Gene Express, Inc. Miscellaneous Commercial ServicesCommercial Services Gene Express, Inc. provides research and development on molecular diagnostic products. It also provides genomic data to accelerate and enable drug and molecular diagnostic development. The company was founded in 1992 and is headquartered in Wilmington, NC. | Commercial Services |
Aerie Pharmaceuticals, Inc.
 Aerie Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on January 1, 2005 and is headquartered in Durham, NCForth Worth, TX. | Health Technology |
Allergan Ltd. (Ireland)
 Allergan Ltd. (Ireland) Pharmaceuticals: MajorHealth Technology Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1982 and is headquartered in Dublin, Ireland. | Health Technology |
- Stock Market
- Insiders
- Michael Rowe
